Could a traditional chinese medicine compound boost prostate cancer treatment?
NCT ID NCT07163910
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding homoharringtonine (a drug from a Chinese evergreen plant) to standard hormone therapy before prostate removal can improve outcomes for men with high-risk or advanced prostate cancer. About 93 participants will receive the drug combination before surgery, and researchers will measure how many achieve a complete or major response. The goal is to find a more effective neoadjuvant treatment for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
homoharringtonine (a plant-derived chemotherapy drug) combined with androgen deprivation therapy (hormone therapy)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option to improve outcomes for men with advanced or high-risk prostate cancer.
What could go wrong
This is a small, early-phase trial (Phase 2) with no control group, so results may not prove effectiveness. The drug can cause side effects like bone marrow suppression and heart rhythm issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••